In vitro studies to assess the inhibitory or inductor effects of tapentadol over the main seven isoforms of CYP implicated in the metabolism of medications CYP2D6, CYP3A4, CYP1A2, CYP2A6, CYP2C9, CYP2C19 y CYP2E1 have revealed that tapentadol is not significantly metabolized by the CYP enzymes, and does not inhibit or induce the activity of any of the CYP isoforms assessed, except for the CYP2D6, which, however, is considered clinically irrelevant 12,24,26,41.
Estudios in vitro para evaluar los efectos inhibidores o inductores del tapentadol sobre las 7 principales isoformas de CYP implicadas en el metabolismo de fármacos CYP2D6, CYP3A4, CYP1A2, CYP2A6, CYP2C9, CYP2C19 y CYP2E1 han revelado que el tapentadol no sufre un metabolismo significativo por las enzimas CYP, y no inhibe ni induce la actividad de ninguna de las isoformas CYP evaluadas, excepto la CYP2D6; no obstante, dicha influencia no se considera de relevancia clínica 12,24,26,41.